Literature DB >> 21128012

Gastrointestinal cancer educational case series: management of metastatic adenocarcinoma of unknown primary origin in a Ph+ ALL survivor.

Celina Ang1, Eileen M O'Reilly, Ghassan K Abou-Alfa, Ali Shamseddine, Hadi Skouri, Ayman Tawil, Mohamad A Eloubeidi, Maeve Lowery, Mohamed Kharfan-Dabaja, Tania Kaprealian, Sally Temraz, Hassan Sibai, Hassan Farran, Manish A Shah.   

Abstract

INTRODUCTION: Secondary malignancies and chronic end-organ sequelae are significant and steadily rising consequences of cancer therapy. The workup and management of a carcinoma of unknown primary must consider the patient's clinical presentation, radiologic and pathologic findings, and comorbidities. CASE REPORT: We present the case of a 50-year-old female survivor of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with significant treatment-related end-organ sequelae who developed a metastatic adenocarcinoma of unknown primary 15 years following curative therapy for her ALL. The complex management issues related to the investigations and choice of therapy for this patient are reviewed. DISCUSSION: This case discusses key issues related to the workup and management of a carcinoma of unknown primary. In addition, it illustrates the importance of taking patient comorbidities into consideration and tailoring investigations and therapy accordingly.

Entities:  

Mesh:

Year:  2011        PMID: 21128012     DOI: 10.1007/s12029-010-9233-1

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  12 in total

Review 1.  Are survivors of acute lymphoblastic leukemia (ALL) at increased risk of cardiovascular disease?

Authors:  Kevin C Oeffinger
Journal:  Pediatr Blood Cancer       Date:  2008-02       Impact factor: 3.167

2.  Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.

Authors:  Gauri R Varadhachary; Dmitri Talantov; Martin N Raber; Christina Meng; Kenneth R Hess; Tim Jatkoe; Renato Lenzi; David R Spigel; Yixin Wang; F Anthony Greco; James L Abbruzzese; John D Hainsworth
Journal:  J Clin Oncol       Date:  2008-09-20       Impact factor: 44.544

3.  Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.

Authors:  Steven E Lipshultz; Stuart R Lipsitz; Stephen E Sallan; Virginia M Dalton; Suzanne M Mone; Richard D Gelber; Steven D Colan
Journal:  J Clin Oncol       Date:  2005-04-20       Impact factor: 44.544

Review 4.  MicroRNAs in cancer: small molecules with a huge impact.

Authors:  Marilena V Iorio; Carlo M Croce
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

5.  Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.

Authors:  S E Lipshultz; S R Lipsitz; S M Mone; A M Goorin; S E Sallan; S P Sanders; E J Orav; R D Gelber; S D Colan
Journal:  N Engl J Med       Date:  1995-06-29       Impact factor: 91.245

Review 6.  Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort.

Authors:  Anna T Meadows; Debra L Friedman; Joseph P Neglia; Ann C Mertens; Sarah S Donaldson; Marilyn Stovall; Sue Hammond; Yutaka Yasui; Peter D Inskip
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

7.  Hepatocellular carcinoma in two patients with cardiac cirrhosis.

Authors:  Teddy Saliba; Stephan Dorkhom; Eileen M O'Reilly; Emmy Ludwig; Bolorsukh Gansukh; Ghassan K Abou-Alfa
Journal:  Eur J Gastroenterol Hepatol       Date:  2010-07       Impact factor: 2.566

8.  Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.

Authors:  S E Lipshultz; S D Colan; R D Gelber; A R Perez-Atayde; S E Sallan; S P Sanders
Journal:  N Engl J Med       Date:  1991-03-21       Impact factor: 91.245

Review 9.  FDG PET/CT in carcinoma of unknown primary.

Authors:  Thomas C Kwee; Sandip Basu; Gang Cheng; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-31       Impact factor: 9.236

10.  Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.

Authors:  Rajen Mody; Suwen Li; Douglas C Dover; Stephen Sallan; Wendy Leisenring; Kevin C Oeffinger; Yutaka Yasui; Leslie L Robison; Joseph P Neglia
Journal:  Blood       Date:  2008-03-11       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.